<DOC>
	<DOC>NCT01902992</DOC>
	<brief_summary>This study will assess efficacy and safety of intraseasonal specific short-term immunotherapy with Depiquick® Birch in patients with allergic rhinitis and or rhinoconjunctivitis with or without intermittent asthma that have a clinical relevant IgE-mediated allergic sensitization against birch pollen. The term "intraseasonal" means that patients will start with immunotherapy treatment during the birch pollen season, i.e. when the already experience allergic symptoms.</brief_summary>
	<brief_title>Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<criteria>Inclusion criteria: 1. Patients must experience significant allergic symptoms on visit 2 2. Medical history of allergic rhinitis and/or rhinoconjunctivitis with clinically relevant sensitization to tree allergens 3. Specific IgE against birch allergens (CAP RAST ≥ 2) Exclusion criteria: 1. History of significant clinical manifestations of allergy as a result of sensitization against grass or weed pollen and perennial allergens 2. FEV1 or PEF value ≤ 80 % 3. Persistent asthma (GINA ≥ 2) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>